The single-shot vaccination is an adenovirus-based technology.
Crucell commenced its Phase I study of the ebola vaccine that it is developing in partnership with the Vaccine Research Center (VRC) of the NIAID . The randomized, double-blind, placebo-controlled study in 48 healthy volunteers will test the single-shot vaccination in a dose-escalation trial.
“We are proud that another of our vaccines is progressing to the clinic, and the Ebola vaccine is the first employing our adenovirus vaccine technology to do so,” says Jaap Goudsmit, CSO at Crucell.
Crucell entered into a CRADA with the VRC to jointly develop, test, and manufacture an adenovirus-based Ebola vaccine. Under the terms of the agreement, Crucell has an option for exclusive worldwide commercialization rights to the Ebola vaccine resulting from this collaboration.